Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Bristol-Myers Squibb begins phase 3 enrollment after psoriasis drug shows high skin clearance

fiercebiotechSeptember 13, 2018

Tag: clinical research , psoriasis , tyrosine kinase inhibitors

PharmaSources Customer Service